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Abstract
Purpose: Recently, familial paraganglioma (PGL) was
shown to be caused by mutations in the gene encoding
succinate dehydrogenase subunit D (SDHD). However, the
prevalence of SDHD mutations in apparently sporadic PGL
is unknown. We studied the frequency and spectrum of
germ-line and somatic SDHD mutations in patients with
parasympathetic PGL.
Experimental Design: We studied 57 unselected patients
who developed parasympathetic PGLs (n 105 tumors) and
who were treated between 1987 and 1999 at the Erasmus
MC (Rotterdam, the Netherlands). Thirty-eight (67%) of
these patients (n  51 tumors) lacked a family history of
parasympathetic PGL. We used conformation-dependent
gel electrophoresis and sequence determination analysis of
germ-line and tumor DNA to identify SDHD mutations. We
compared the clinical and molecular characteristics of spo-
radic and hereditary PGLs.
Results: Three different SDHD germ-line mutations
were identified in 32 of the 57 (56%) patients. These in-
cluded 19 of 19 (100%) patients with familial PGL and also
13 of 38 (34%) patients with apparently sporadic PGL. All
three mutations were characterized as missense mutations
(D92Y, L95P, and L139P) in highly conserved regions of the
SDHD gene and were not observed in 200 control alleles. No
somatic mutations were found.
Conclusions: Germ-line mutations of the SDHD gene
are present in a significant number of patients with appar-
ently sporadic parasympathetic PGL. Somatic SDHD muta-
tions do not play a significant role in the sporadic form of
this tumor. Genetic testing for SDHD germ-line mutations
should be considered for every patient presenting with this
tumor, even if a personal or family history of PGL is absent,
to allow appropriate clinical management.
Introduction
Parasympathetic PGLs3 are highly vascularized, slow-
growing tumors of parasympathetic ganglia, mostly of the head
and neck region. The annual incidence is estimated at 1 in
30,000, and the tumors typically present in the fourth or fifth
decade (1, 2). The tumor most commonly presents as a painless
neck mass or with symptoms due to compression and damage of
the surrounding structures. Depending on the anatomical local-
ization, cranial nerve damage may cause bradycardia, hoarse-
ness, or hearing loss. Approximately 1% of the tumors produce
catecholamines. Progression to malignancy occurs in 2–10% of
cases and can only be determined by detection of metastatic
spread, particularly to the lymph nodes and lungs. There are
currently three treatment strategies: (a) surgery; (b) radiation
therapy; or (c) observation (3). Because tumor growth as well as
surgery can cause disabling loss of function, preoperative esti-
mation of tumor growth is an important parameter influencing
clinical management. A “wait and scan” approach is thus often
considered, although surgical resection remains the mainstay of
the curative treatment of parasympathetic PGLs (4, 5).
Familial occurrence is observed in a significant minority
(approximately 20%) of cases, with an autosomal dominant
mode of transmission with incomplete and age-dependent pen-
etrance (6–8). The female predominance in sporadic PGL with
equal sex distribution in familial patients and an almost exclu-
sively paternal inheritance pattern in these families suggest
maternal imprinting of the disease gene (9). Clinical features
that suggest a genetic predisposition in a given patient include
bilateral or multiple PGLs and an unusually young age (before
the third decade) at presentation. Linkage analysis and loss of
heterozygosity studies in unrelated and multigenerational fam-
ilies with hereditary PGL (Mendelian Inheritance Man number
168,000) have provided evidence for the existence of two dis-
tinct PGL susceptibility genes on chromosome 11, PGL1 at
11q23 and PGL2 at 11q13, both of which are thought to be
maternally imprinted (10, 11). Recently, the SDHD gene, which
maps to the PGL1 locus, has been implicated as the putative
disease gene because inactivating germ-line SDHD mutations
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have been detected in PGL families (12). SDHD germ-line
mutations were also recently described in a few cases of familial
pheochromocytoma, and to date, only one sporadic mutation has
been reported (13).
The SDHD gene, which comprises four exons and three
introns extending over 19 kb, encodes a 159-amino acid protein.
This protein constitutes the small subunit (cybS) of cytochrome
b in the mitochondrial enzyme complex II (succinate-ubiqui-
none oxidoreductase) and plays an important role in both the
citric acid cycle and the aerobic respiratory chain (14). Recently,
it has been demonstrated that germ-line mutations in succinate
dehydrogenase subunit C (SDHC) and succinate dehydrogenase
subunit B (SDHB), encoding two other components of complex
II, also predispose individuals to hereditary PGL (15, 16).
Whether genetic alterations of the SDHD gene play a role
in the pathogenesis of sporadic parasympathetic PGL is pres-
ently unknown. Also, the prevalence of germ-line SDHD mu-
tations among apparently sporadic PGL patients has not been
studied. Further knowledge of the contribution and nature of
gene mutations involved in PGL tumorigenesis could provide
early diagnosis and allow accurate genetic counseling in af-
fected families. Therefore, we assessed the frequency and type
of SDHD mutations in an unselected series of patients with
parasympathetic PGLs treated at our hospital, including both
familial and apparently sporadic cases.
Patients and Methods
Patients. Individuals who received a diagnosis of para-
sympathetic PGL between May 1987 and December 1999 were
identified by retrospectively reviewing the records of the Pa-
thology Department at the Erasmus MC. Of the 89 PGL patients
eligible to participate, specimens and constitutional DNA from
57 patients were available for retrieval and testing. Information
on medical and family histories was obtained by direct inter-
views and by review of the medical charts. The presence of
multiple tumors was assessed by review of the radiology reports
of SRS and/or magnetic resonance imaging. From 48 patients,
SRS and/or magnetic resonance imaging reports were available
[41 patients (72%) underwent SRS]. Of the nine patients without
such information, four had histopathological diagnoses of bilat-
eral or multiple tumors. The average follow-up period was 52
months (range, 1–218 months), with no significant difference
between familial and apparently sporadic patients.
A total of 105 parasympathetic PGLs was observed in the
57 patients, of which 78 tumors and matched normal tissues
were available for analysis. After coupling of the clinical infor-
mation to the pathology specimen, both patient information and
DNA samples were anonymized to preserve the confidentiality
of the patients and in accordance with the Erasmus MC guide-
lines for studies involving patient data and tissues. A tumor was
considered sporadic if the patient did not know any relative with
PGL.
Control DNA consisted of 100 encoded peripheral blood
samples from persons residing in the same geographic area,
randomly selected from the blood bank (Bloedbank ZWN Rot-
terdam, the Netherlands).
In addition, 13 PGLs from 13 patients residing in other
geographic areas (from hospitals in the south of the Netherlands
and Belgium) were investigated for exon 3 SDHD mutations.
Clinical Database. A collective database of clinical and
molecular features was prepared. The date of the patient’s first
biopsy or resection with a histopathological diagnosis of para-
sympathetic PGL was recorded as the date of diagnosis. The age
of onset was defined as the age at which the patient first
experienced symptoms. Three patients (two women and one
man) were related to one another, and an additional two patients
belonged to another family. For each patient, we recorded the
place of birth, age of onset and diagnosis, clinical history, the
patient’s family history with respect to parasympathetic PGL,
the laterality/multifocality of the tumors, and the presence of
any metastases.
DNA Preparation and SSCP Analysis. Fresh frozen or
formalin-fixed, paraffin-embedded tumor and normal tissues
from all patients, including 78 of the 105 tumors, were retrieved
from the archives of the Pathology Department of the Erasmus
MC. Paraffin blocks containing tumor and normal tissues were
obtained from 13 patients residing in other areas [kindly pro-
vided by Prof. Dr. E. Van Marck (Department of Pathology,
University Hospital Antwerp, Antwerp, Belgium), Dr. G. van
Lijnschoten (Society for Pathological Anatomy and Medical
Microbiology, Eindhoven, the Netherlands), and Dr. A. P. de
Bruı¨ne (Department of Pathology, University of Maastricht,
Maastricht, the Netherlands)].
From each specimen, regions containing at least 80% neo-
plastic cells were selected. DNA from 12 freshly frozen tumors
was isolated using the D-5000 Pure gene DNA isolation kit
(Gentra Systems, Minneapolis, MN) according to the manufac-
turer’s recommendations. DNA from 66 paraffin-embedded tu-
mors and all normal tissues was extracted by standard detergent-
proteinase K lysis, followed by phenol-chloroform extraction
and ethanol precipitation, as described previously (17).
The entire open reading frame of the SDHD gene and all
exon-intron boundaries were investigated with the PCR primers
described previously (12). PCR amplification of tumor DNA
and matched normal DNA was performed in 15-l reaction
mixtures containing 1.5 mM MgCl2; 10 mM Tris-HCl; 50 mM
KCl; 0.02 mM dATP; 0.2 mM dGTP, dTTP, and dCTP; 0.8 Ci
of [-32P]dATP (Amersham, Buckinghamshire, United King-
dom); 20 pmol of each sense and antisense primer; and 1 unit of
Taq DNA polymerase (Amplitaq Gold; Perkin-Elmer, Norwalk,
CT). The amplification profile consisted of an initial denatur-
ation step at 94°C for 5 min, followed by 35 cycles of denatur-
ation at 94°C for 45 s, annealing at 55 for 60 s, and extension at
72°C for 60 s. A final extension step was carried out at 72°C for
10 min. Electrophoresis of PCR products was carried out over-
night at 8 W on nondenaturing gels containing 8% polyacryl-
amide (49:1) and 10% (v/v) glycerol. For the exon 4 amplicons,
electrophoresis was performed on an 8% polyacrylamide gel
without glycerol for 6 h at 4°C and 20 W. The gels were dried
and exposed to X-ray film overnight at 70°C.
DNA Sequencing. For each variant pattern identified by
SSCP analysis, two independent genomic DNA samples were
amplified for direct sequencing, or the aberrant PCR product
was cloned and reamplified with the original primer pair. These
products were bidirectionally sequenced using Applied Biosys-
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tems Taq DyeDeoxy terminator cycle sequencing (Baseclear,
Leiden, the Netherlands).
Statistics. Correlations between a specific SDHD muta-
tion and clinical features were tested by use of the 2 test or an
unpaired t test. Ps  0.05 were considered statistically signifi-
cant.
Results
Patient Characteristics. The characteristics of the pa-
tients and their tumors are shown in Table 1. The group of 19
patients with a positive family history of PGL showed a roughly
equal sex distribution (42% male versus 58% female), whereas
there was a female predominance in patients without a family
history of PGL (34% male versus 66% female). The mean age
at onset was earlier in patients with a positive family history
(P  0.04). The majority of patients with a single PGL tumor
had no family history, and bilateral carotid body tumors and
multiple tumors were generally associated with a positive family
history (P  0.0001).
The carotid body was the most common site of origin
(52%) and comprised 33 of 51 (64%) tumors in familial PGL
patients. Tympanic nerve PGLs occurred more frequently in
apparently sporadic patients (P  0.035), with other sites being
equally distributed between the two groups.
None of the patients had evidence of metastatic disease at
the end of our study. Of the 57 patients, only 1 young patient
(1.8%) had evidence of a malignant PGL (tumors cells were
detected in one lymph node after total resection of a carotid
body tumor). After 141 months of follow-up, she is alive and
well.
Seven patients developed a recurrence after resection of a
single PGL, which was either a tympanic, jugular, or vagal
tumor. None of these patients had a positive family history.
Identification of SDHD Gene Mutations. SSCP analy-
sis revealed four different aberrant patterns, which were present
in 49 of 78 (63%) PGL specimens. In each instance, the same
SSCP variant was also found in the germ-line DNA of the
patient (totaling 33 of 57 patients; 58%). By sequence analysis,
the aberrant patterns, which were all located in exon 3 and exon
4, were found to correspond to three different missense SDHD
mutations and one SNP. All three missense mutations were
located in highly conserved regions and were absent from the
200 control alleles. The specific D92Y missense mutation was
observed in 22 patients, the L95P mutation was observed in 9
patients, and the L139P mutation was observed in 1 patient.
Altogether, germ-line SDHD missense mutations were identi-
fied in 32 of 57 (56%) patients.
The SNP, which does not result in an amino acid substi-
tution in the SDHD protein, involved a change in codon 68
(AGC3AGT). This sequence alteration was also observed in
one of the 200 control alleles and is therefore regarded as an
uncommon polymorphism apparently not associated with hered-
itary PGL.
Examples of SSCP analysis and sequence determination in
patients with SDHD missense mutations are shown in Fig. 1A.
Patient Characteristics Associated with SDHD Muta-
tions. A germ-line SDHD mutation was associated with a
positive family history for PGL in 19 of 32 (59%) patients but
was associated with a negative family history for PGL in 13 of
32 (41%) patients (Table 2). The mean age of onset in patients
harboring a germ-line missense mutation was 40.3 11.4 years,
compared with 44.9  14.2 years in patients without a SDHD
mutation, which is not a significant difference. The difference in
age of onset also did not differ significantly among the specific
mutations. Eighty-eight percent of patients without a SDHD
mutation had a single PGL tumor, whereas in patients with
Table 1 Clinical characteristics of 57 PGL patients evaluated for SDHD mutations
Characteristic All patients (N  57)
Patients with positive
family historya
(N  19)
Patients with negative
family historya
(N  38) Pb
Patient
Sex [no. (%)] 0.56
Male 21 (37) 8 (42) 13 (34)
Female 36 (63) 11 (58) 25 (66)
Mean age of onset  SE (yrs) 42.4  12.4 37.3  8.2 45.0  14.1 0.04
Mean follow-up time [months (range)] 52 (1–218) 57 (1–166) 49 (1–218) 0.56
Tumor focality [no. (%)] 0.0001c
Single PGL 30 (53) 2 (10) 28 (74)
Recurrence 7 (12) 7 (18)
Bilateral carotid body 10 (17) 7 (37) 3 (8)
Multiple 17 (30) 10 (53) 7 (18)
Site of tumor [no. (%)] N  105 N  51 N  54
Carotid body 55 (52) 33 (64) 22 (41) 0.17
Vegal nerve 17 (16) 8 (16) 9 (17)
Tympanic nerve 15 (14) 3 (6) 12 (22) 0.035
Jugular nerve 13 (13) 6 (12) 7 (13)
Mediastinal 4 (4) 1 (2) 3 (5)
Spinal cord 1 (1) 0 (0) 1 (2)
a Family history data as reported at the time of the original interview.
b We used the 2 test to compare all variables except mean age at onset and mean follow-up time, for which we used an unpaired t test.
c P is for comparison of single PGL with bilateral and multiple PGL.
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SDHD aberrations, bilateral and multiple PGLs were most com-
mon (75%).
Of seven patients with recurrence of a single PGL, four
patients harbored a germ-line SDHD mutation. We did not
detect a germ-line SDHD mutation in the patient with metastatic
spread in a lymph node.
SDHD Mutations in Patients Residing in Other Geo-
graphic Areas. To further investigate whether the recurrent
mutations could be regarded as founder mutations, we analyzed 13
patients from hospitals in the south of the Netherlands and Belgium
for exon 3 mutations. Five (38%) of these patients harbored a
germ-line SDHD mutation in exon 3, including the Dutch founder
Fig. 1. SDHD alterations identified in
PGL patients by SSCP analysis and di-
rect sequencing. SSCP patterns of the
tumor (T) and germ-line (N) DNA are
shown from all SDHD alterations. C,
normal control sample. A shows the
three missense mutations (D92Y, L95P,
and L139P, respectively). B shows two
new mutations found in 5 of 13 patients
residing in other geographic areas. Left,
the frameshift mutation caused by dele-
tion of the first thymidine in codon 93,
resulting in a premature stop codon in
exon 4. Right, the splice site mutation
(ag3at) at the boundary of intron 2 and
exon 3 is shown. The autoradiographs of
PCR-SSCP gels show the migration pat-
terns of normal DNA (black arrow-
heads) and the mobility shifts produced
by aberrant alleles (red arrowheads).
The sequencing chromatograms below
each autoradiograph show the alter-
ations (note the substituted nucleotide
marked by an asterisk). In samples that
were cloned before sequencing, the nor-
mal sequence is absent, whereas in di-
rect sequenced samples, both normal
and aberrant sequences are present.
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mutation D92Y (three patients), a mutation resulting in a change of
a splice site (5 intron 2-. . . gtat-3 exon 3), and a frameshift
mutation caused by deletion of the first thymidine in codon 93 and
resulting in a premature stop codon in exon 4 (Fig. 1B).
Discussion
PGL is the only well-documented manifestation of the hered-
itary PGL syndrome, in which SDHD gene mutations apparently
represent an early and essential pathogenic event (12). We identi-
fied SDHD mutations in 32 of 57 (56%) unselected patients. This
supports the prediction that the SDHD gene has an important role
in the pathogenesis of parasympathetic PGL. All SDHD mutations
identified in this study were present in the patients’ germ-line
DNA, including 	30% of patients with a negative family history
for PGL. These data indicate that family history is a poor indicator
of the risk of hereditary PGL and that screening for germ-line
SDHD mutations is clinically relevant in all patients presenting
with parasympathetic PGLs.
SSCP screening for the presence of mutations revealed four
different aberrant patterns. Upon sequencing, three aberrations
proved to be missense mutations (D92Y, L95P and L139P),
whereas the remaining one was a silent substitution SNP. These
mutations could theoretically be clinically unimportant polymor-
phisms. However, we regard the missense mutations found in this
study as pathogenic because they occur at highly conserved resi-
dues of the SDHD protein, they were absent from 200 control
alleles, and finally, the D92Y and L95P mutations have been
reported independently as pathogenic in familial PGL (12, 18).
All SDHD mutations identified in our study were present in
the germ-line DNA; no somatic SDHD mutations were found.
Recently, one somatic SDHD mutation was described in a
pheochromocytoma (13). These results imply that the involve-
ment of the SDHD gene is restricted to inherited cases of PGL.
It is of interest that only three different SDHD mutations
were found in the 32 patients with mutated SDHD, with two of
them, D92Y and L95P, comprising 97% of the mutations de-
tected in this study. This indicates that either these mutations are
ancient or that the affected persons are more closely related than
known. Information on places of birth in this cohort of patients
is suggestive of a founder effect, although some of the patients
originate from other European and non-European countries.
Baysal et al. (12) previously reported the specific D92Y muta-
tion in a Dutch founder population (19). To further investigate
whether this founder mutation occurs in patients from other
geographic areas, we analyzed 13 patients from hospitals in the
south of the Netherlands and Belgium for exon 3 mutations.
Aside from the Dutch founder mutation, we also found two new
mutations, supporting evidence for founder effects.
The finding of the same germ-line SDHD mutations in famil-
ial and sporadic cases points most likely to reduced penetrance of
the mutated SDHD gene, although the occurrence of de novo hot
spot mutations cannot be completely ruled out. Mutational and
haplotype analysis of patients and family members would provide
additional information on the origin of the mutations.
In all of the 19 familial PGL patients, a SDHD mutation
was detected, indicating a high mutation detection sensitivity for
SSCP analysis. However, in the apparently sporadic PGL pa-
tients, we cannot rule out the possibility that SDHD mutations
escaped detection by SSCP (20). Furthermore, mutations can be
present in the SDHD gene outside the screened sequences. It is
known that gene mutations in the untranslated regions can
severely affect RNA stability. Finally, in some apparently spo-
radic patients, a germ-line mutation in another gene may cause
PGL. Recently, germ-line mutations in the SDHC and SDHB
genes have been demonstrated to cause autosomal dominant
PGL syndromes as well (15, 16).
Table 2 Genetic findings and correlations to patient characteristics
Characteristic
SDHD gene alteration
Pa
All missense
(N  32)
D92Y
(N  22)
L95P
(N  9)
No alteration
(N  25)
Patient [no. (%)]
Sex 0.38
Male (n  21) 14 10 4 7
Female (n  36) 18 12 5 18
Mean age of onset  SE (yrs) 40.3  11.4 38.6  9.9 44.8  14.1 44.9  14.2 0.21
Tumor focality [no (%)] 0.0001
Single PGL (n  30) 8 5 3 22
Bilateral carotid body (n  10) 9 7 2 1
Multiple (n  17) 15b 10 4 2
Family history [no. (%)] 0.0001
Positive (n  19) 19b 13 5
Single PGL (n  2) 2 2
Bilateral carotid body (n  7) 7 6 1
Multiple (n  10) 10b 7 2
Negative (n  38) 13 9 4 25
Single PGL (n  28) 6 5 1 22
Recurrence 4 3 1 3
Bilateral carotid body (n  3) 2 1 1 1
Multiple (n  7) 5 3 2 2
a The Ps resulted from 2 tests to compare all variables except mean age of onset, for which we used an unpaired t test. All Ps are for the
differences between patients with and without a missense mutation.
b Includes the patient harboring the L139P mutation.
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As shown, a positive family history of PGL is the main
parameter associated with SDHD gene mutations (19 of 19
patients), followed by the presence of bilateral or multiple PGLs
(24 of 27 patients). Importantly, in patients without a family
history of PGL, bilateral or multiple tumors, but not early age at
onset, pointed toward a germ-line SDHD gene mutation. In the
28 patients presenting with a single PGL tumor and lacking a
family history of PGL, six germ-line SDHD mutations were
found (21%). No clinical parameter was significantly correlated
with any of the three mutations, but the study size precludes the
detection of small differences.
These results show that clinical and patient data have limited
value in indicating germ-line SDHD mutations. Comparable results
were reported for apparently sporadic medullary thyroid carcinoma
patients, who appeared to have germ-line RET gene mutations in
about 10% of cases (21). The authors show that, despite this low
percentage, the genetic analysis of all apparently sporadic medul-
lary thyroid carcinoma patients is cost-effective.
Genetic counseling on the basis of DNA linkage analysis in
PGL families has previously been described by Oosterwijk et al.
(22). Their results indicate that screening of all PGL patients
may further affect counseling strategies because the detection of
germ-line SDHD mutations in apparently sporadic patients is
likely to improve early diagnosis of PGL, which will support
adequate and appropriate clinical follow-up and management.
On the other hand, we have no data on the lifetime risk of PGLs
in people harboring a germ-line SDHD mutation. More data are
needed to allow a valid estimate of the risk of parasympathetic
PGL in patients with SDHD mutations. However, our data do
support the conclusion that SDHD mutation screening should be
considered in every patient presenting with this tumor.
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